BACKGROUND: About 20% of women with ovarian cancer have low concentrations of serum cancer antigen 125 (CA125), and this important tumor marker cannot be used to monitor their disease. The measured concentration for mucin 1 (MUC1), or CA15-3, another tumor marker, can be lowered in breast and ovarian cancer patients when circulating immune complexes (CICs) containing antibodies bound to the free antigen are present. Because CA125 and MUC1 are related members of the mucin family, we sought to determine whether CICs might also exist for CA125 and interfere with its clinical assay. METHODS: We developed an antigen capture-based assay to determine the presence of CICs for CA125. We spotted mouse antibodies to CA125 onto nanoparticle slides, incubated them with patient serum, and added Cy5-tagged goat antihuman IgG antibodies. Fluorescence intensities were read and normalized to the intensities for glutathione S-transferase A1 as a control. RESULTS: Assay results for 23 ovarian cancer cases with high CA125 concentrations, 43 cases with low CA125 concentrations, and 19 controls (mean CA125 concentrations, 2706, 23, and 11 kilounits/L, respectively) revealed mean fluorescence intensities for CA125 CIC of 2.30, 2.72, and 1.99 intensity units (iu), respectively. A generalized linear model adjusted for batch and age showed higher CA125 CIC fluorescence intensities in low-CA125 cases than in high-CA125 cases (P = 0.03) and controls (P = 0.0005). Four ovarian cancer patients who had recurrent disease and always had low CA125 values had a mean CA125 CIC value of 3.06 iu (95% CI, 2.34-4.01 iu). CONCLUSIONS: These preliminary results suggest the existence of CICs involving CA125, which may help explain some ovarian cancer cases with low CA125 concentrations.
BACKGROUND: About 20% of women with ovarian cancer have low concentrations of serum cancer antigen 125 (CA125), and this important tumor marker cannot be used to monitor their disease. The measured concentration for mucin 1 (MUC1), or CA15-3, another tumor marker, can be lowered in breast and ovarian cancerpatients when circulating immune complexes (CICs) containing antibodies bound to the free antigen are present. Because CA125 and MUC1 are related members of the mucin family, we sought to determine whether CICs might also exist for CA125 and interfere with its clinical assay. METHODS: We developed an antigen capture-based assay to determine the presence of CICs for CA125. We spotted mouse antibodies to CA125 onto nanoparticle slides, incubated them with patient serum, and added Cy5-tagged goat antihuman IgG antibodies. Fluorescence intensities were read and normalized to the intensities for glutathione S-transferase A1 as a control. RESULTS: Assay results for 23 ovarian cancer cases with high CA125 concentrations, 43 cases with low CA125 concentrations, and 19 controls (mean CA125 concentrations, 2706, 23, and 11 kilounits/L, respectively) revealed mean fluorescence intensities for CA125CIC of 2.30, 2.72, and 1.99 intensity units (iu), respectively. A generalized linear model adjusted for batch and age showed higher CA125CIC fluorescence intensities in low-CA125 cases than in high-CA125 cases (P = 0.03) and controls (P = 0.0005). Four ovarian cancerpatients who had recurrent disease and always had low CA125 values had a mean CA125CIC value of 3.06 iu (95% CI, 2.34-4.01 iu). CONCLUSIONS: These preliminary results suggest the existence of CICs involving CA125, which may help explain some ovarian cancer cases with low CA125 concentrations.
Authors: Y Hinoda; N Nakagawa; H Nakamura; Y Makiguchi; F Itoh; M Adachi; T Yabana; K Imai; A Yachi Journal: Immunol Lett Date: 1993-02 Impact factor: 3.685
Authors: Brian C Cooper; Anil K Sood; Charles S Davis; Justine M Ritchie; Joel I Sorosky; Barrie Anderson; Richard E Buller Journal: Obstet Gynecol Date: 2002-07 Impact factor: 7.661
Authors: G D Malkasian; R C Knapp; P T Lavin; V R Zurawski; K C Podratz; C R Stanhope; R Mortel; J S Berek; R C Bast; R E Ritts Journal: Am J Obstet Gynecol Date: 1988-08 Impact factor: 8.661
Authors: R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp Journal: N Engl J Med Date: 1983-10-13 Impact factor: 91.245
Authors: Edward Partridge; Aimee R Kreimer; Robert T Greenlee; Craig Williams; Jian-Lun Xu; Timothy R Church; Bruce Kessel; Christine C Johnson; Joel L Weissfeld; Claudine Isaacs; Gerald L Andriole; Sheryl Ogden; Lawrence R Ragard; Saundra S Buys Journal: Obstet Gynecol Date: 2009-04 Impact factor: 7.623
Authors: Judith L Luborsky; Yi Yu; Seby L Edassery; Jade Jaffar; Yuan Yee Yip; Pu Liu; Karl Eric Hellstrom; Ingegerd Hellstrom Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-08-16 Impact factor: 4.254
Authors: Renée T Fortner; Helena Schock; Charlotte Le Cornet; Anika Hüsing; Allison F Vitonis; Theron S Johnson; Raina N Fichorova; Titilayo Fashemi; Hidemi S Yamamoto; Anne Tjønneland; Louise Hansen; Kim Overvad; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Gianluca Severi; Heiner Boeing; Antonia Trichopoulou; Eleni-Maria Papatesta; Carlo La Vecchia; Domenico Palli; Sabina Sieri; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; N Charlotte Onland-Moret; Petra H Peeters; H B As Bueno-de-Mesquita; Elisabete Weiderpass; J Ramón Quirós; Eric J Duell; Maria-Jose Sánchez; Carmen Navarro; Eva Ardanaz; Nerea Larrañaga; Björn Nodin; Karin Jirström; Annika Idahl; Eva Lundin; Kay-Tee Khaw; Ruth C Travis; Marc Gunter; Mattias Johansson; Laure Dossus; Melissa A Merritt; Elio Riboli; Kathryn L Terry; Daniel W Cramer; Rudolf Kaaks Journal: Int J Cancer Date: 2017-12-11 Impact factor: 7.396
Authors: Wei-Lei Yang; Zhen Lu; Jing Guo; Bryan M Fellman; Jing Ning; Karen H Lu; Usha Menon; Makoto Kobayashi; Samir M Hanash; Joseph Celestino; Steven J Skates; Robert C Bast Journal: Cancer Date: 2019-11-12 Impact factor: 6.860